文献速递心境障碍

TSPO分布容积预测塞来昔布开放标签试验中重性抑郁障碍症状减轻

Translocator Protein Distribution Volume Predicts Reduction of Symptoms During Open-Label Trial of Celecoxib in Major Depressive Disorder.
PubMed 文献 · Biol Psychiatry · 2020-03-29

该研究纳入41例难治性重性抑郁障碍患者,用[18F]FEPPA PET测量前额叶皮层(PFC)和前扣带皮层(ACC)的TSPO总分布容积(VT),并给予开放标签口服塞来昔布200 mg每日两次共8周。结果显示PFC和ACC的TSPO VT与HDRS评分变化呈非线性关系,分别解释84%和92%的方差,提示胶质增生标志物可预测塞来昔布的症状减轻效果。

要点

  • 难治性抑郁患者PFC和ACC的TSPO VT与塞来昔布8周后HDRS减分呈非线性关系。
  • PFC和ACC的TSPO VT分别解释HDRS减分84%和92%的方差。
  • 低TSPO VT时HDRS无减分,随TSPO VT升高减分出现并趋于平台。

核心结论

  • 在TSPO VT标示的胶质增生存在时,塞来昔布给药与更明显的症状减轻相关。
  • TSPO VT对症状减轻具有预测性,支持将胶质增生标志物与靶向胶质增生效应的药物匹配的个体化医学方法。

研究设计与样本

  • 开放标签试验,41例难治性重性抑郁障碍患者接受一次[18F]FEPPA PET扫描测量PFC和ACC的TSPO VT。
  • 给予开放标签口服塞来昔布200 mg每日两次共8周,用17项汉密尔顿抑郁量表(HDRS)测量症状变化。

主要发现

  • 0至8周HDRS评分累积平均变化与PFC和ACC的TSPO VT呈显著非线性关系。
  • 低TSPO VT值时HDRS评分无减轻,随TSPO VT值升高HDRS评分减轻并随后趋于平台。
  • 4参数S形模型显示PFC和ACC的TSPO VT分别解释84%和92%的方差。

关键数值与推荐

  • 塞来昔布剂量为200 mg口服每日两次,疗程8周。
  • 症状变化用17项HDRS测量。
  • PFC和ACC的TSPO VT分别解释HDRS减分84%和92%的方差。

临床怎么用

  • 对难治性重性抑郁障碍,可考虑用TSPO VT作为胶质增生标志物预测塞来昔布类靶向胶质增生药物的症状减轻反应。
  • 该个体化匹配策略宜用于靶向胶质增生效应新药的早期开发。

局限性

  • 原文未报告盲法、对照组或安慰剂设置。
  • 原文未报告除HDRS外的其他临床结局或安全性数据。
  • 原文未报告样本来源、合并用药或随访时长等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gliosis is common among neuropsychiatric diseases, but the relationship between gliosis and response to therapeutics targeting effects of gliosis is largely unknown. Translocator protein total distribution volume (TSPO VT), measured with positron emission tomography, mainly reflects gliosis in neuropsychiatric disease. Here, the primary objective was to determine whether TSPO VT in the prefrontal cortex (PFC) and anterior cingulate cortex (ACC) predicts reduction of depressive symptoms following open-label celecoxib administration in treatment-resistant major depressive disorder. METHODS: A total of 41 subjects with treatment-resistant major depressive disorder underwent one [18F]FEPPA positron emission tomography scan to measure PFC and ACC TSPO VT. Open-label oral celecoxib (200 mg, twice daily) was administered for 8 weeks. Change in symptoms was measured with the 17-item Hamilton Depression Rating Scale (HDRS). RESULTS: Cumulative mean change in HDRS scores between 0 and 8 weeks of treatment was plotted against PFC and ACC TSPO VT, showing a significant nonlinear relationship. At low TSPO VT values, there was no reduction in HDRS scores, but as TSPO VT values increased, there was a reduction in HDRS scores that then plateaued. This was modeled with a 4-parameter sigmoidal model in which PFC and ACC TSPO VT accounted for 84% and 92% of the variance, respectively. CONCLUSIONS: Celecoxib administration in the presence of gliosis labeled by TSPO VT is associated with greater reduction of symptoms. Given the predictiveness of TSPO VT on symptom reduction, this personalized medicine approach of matching a marker of gliosis to medication targeting effects of gliosis should be applied in early development of novel therapeutics, in particular for treatment-resistant major depressive disorder.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Attwells S, Setiawan E, Rusjan PM, et al. Translocator Protein Distribution Volume Predicts Reduction of Symptoms During Open-Label Trial of Celecoxib in Major Depressive Disorder. Biol Psychiatry. 2020. PMID: 32402468. doi:10.1016/j.biopsych.2020.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。